Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ELCC 2026 | Cardiac comorbidities in lung cancer: key challenges and approaching treatment decision-making

Gerard M Walls, MB, MRCP, MSc, FRCR, Queens University, Belfast, UK, discusses the challenges of treating lung cancer patients with cardiac comorbidities, highlighting the need for an individualized approach that considers the patient’s overall quality of life, performance status, and other factors beyond just their medical history. Dr Walls emphasizes the importance of using holistic assessments, such as ECOG performance status, 3LD scores, geriatric assessments, sarcopenia assessments, and ePROMs, to determine the best course of treatment for each patient. This interview took place at the 2026 European Lung Cancer Congress in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.